|
Apr 14
|
WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards
|
|
Mar 11
|
WuXi Biologics Included in S&P Global Sustainability Yearbook 2025
|
|
Mar 4
|
WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
|
|
Feb 27
|
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
|
|
Jan 2
|
WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year
|
|
Oct 9
|
WuXi Biologics (Cayman) Inc (WXXWY) Half Year 2024 Earnings Call Highlights: Navigating Growth ...
|
|
Sep 23
|
WuXi Biologics Included in Hang Seng ESG 50 Index
|
|
Mar 22
|
WuXi Biologics Named to CDP 'A List' for Water Security
|
|
Jan 17
|
WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™
|
|
Jan 10
|
WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates
|
|
Dec 12
|
WuXi Biologics Named to 2023 Dow Jones Sustainability World Index
|
|
Dec 8
|
WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating
|
|
Dec 5
|
China biotech: investors fear a negative reaction from the US
|
|
Apr 28
|
WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability
|